<DOC>
	<DOCNO>NCT01471574</DOCNO>
	<brief_summary>The purpose open label study evaluate safety efficacy daclatasvir plus pegylated interferon-alfa 2a ribavirin untreated hepatitis C virus patient coinfected HIV</brief_summary>
	<brief_title>Safety Efficacy Study Daclatasvir ( BMS-790052 ) Plus Pegylated Interferon-Alfa 2a Ribavirin Patients Coinfected With Untreated Hepatitis C Virus HIV Virus</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Key Males female , 18 70 year age Hepatitis C virus ( HCV ) genotype 1a 1b HCVtreatment naive HCV RNA &gt; 10,000 IU/mL screen HIV1 infection ( approximately 250 patient receive highly active antiretroviral therapy [ HAART ] , 50 patient receive HAART ) For patient receive HAART , HIV RNA must &lt; 40 copies/mL screening must &lt; 400 copies/ml least 6 month prior screen Key Patients receive HAART first initiate antiretroviral therapy within last 6 month Day 1 Patients receive HAART change antiretroviral regimen due safety efficacy associate HIV treatment within last 3 month prior Day 1 . However , change require patient 's HAART regimen meet requirement protocol , change allow screen visit . The patient wait minimum 1 month prior Day 1 repeat HIV viral load confirm , &lt; 40 copies/ mL Use prohibit HAART regimen within 1 month Day 1 throughout treatment period trial ( patient receive HAART change antiretroviral regimen initiate HCV treatment within 6 week prior Day 1 ) Laboratory value : 1 . Neutrophil count &lt; 1500 cells/μL ( &lt; 1200 cells/ μL Blacks ) 2 . Platelet count &lt; 90,000 cells/μL 3 . Hemoglobin ≤12 g/dL female , hemoglobin ≤13 g/dL male 4 . Total bilirubin ≥34 μmol/L ( ≥2 mg/dL ) unless patient document history Gilbert 's disease antiretroviral regimen contain atazanavir 5 . Alanine aminotransferase ≥5*upper limit normal</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>